Aminex Therapeutics, Inc., is a drug development company exclusively focused on development and clinical efficacy of a unique cancer immunotherapy drug in the general category of cancer immunomodulators. Aminex’s novel cancer immunotherapy drug, AMXT 1501/DFMO, engages, in multiple animal trials, the immune system to attack and clear cancer primary tumors and its metastases. AMXT 1501/DFMO negates two major immune system suppressors--polyamines and myeloid-derived suppressor cells (MDSCs). Further, it compromises the cancer-driving roles of both the MYC and RAS oncogenes, thought to be involved with more than sixty percent of solid tumors. DFMO itself is a special drug separately of research interest today in neuroblastoma, colorectal cancer prevention, glioblastoma and Alzheimer’s. AMXT 1501 has been specifically developed to enhance and extend, in conjunction with DFMO, the ability of the immune system to recognize and attack multiple cancers.
Aminex has operated with private funding since its founding in 2009. We have raised about $10 million to date in specific tranches to complete all remaining FDA preclinical requirements for AMXT 1501/DFMO human clinical trials. The final preclinical task, submittal of an Independent New Drug (IND) application to the FDA, is scheduled for January 2018. A planned Series B round of up to $10 million to fund the remainder of the Phase 1/2A human clinical trials will be initiated in the first quarter of 2018.
Aminex has made few scientific presentations and is currently "under the radar". That will change soon with an IND submittal and clinical trial initiation.
An extensive array of animal data supports the likelihood that AMXT 1501/DFMO should be effective in human cancer clinical trials. Initial signals of efficacy in cancer patients with solid tumors could be observed as early as late 2018. Our vision is for AMXT 1501/DFMO to be a foundational and transformational drug therapy, for use alone or in combination with other immunotherapy treatments. AMXT 1501/DFMO’s small molecule design and low chemical production costs will allow substantial pricing flexibility compared to the pricing of current biologics and cell therapy treatments. Aminex believes AMXT 1501/DFMO has low adverse effects risk and high likelihood of major benefit for mankind.